Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies

Figure 2

The TCRB repertoire diversity in bDMARD-treated RA patients. (a) TCRB clonotypes of RA patients receiving adalimumab only (A1 and A2), adalimumab followed by rituximab (R1, R2, and R3), and adalimumab followed by tocilizumab (T1, T2, and T3) are represented as dots and ranked according to clonal frequency from high to low. The diversity index of the TCRB repertoire for each patient was calculated as the inverse Simpson diversity index (). (b) The boxplot shows the comparison of TCRB repertoire diversity between RA patients receiving different courses of bDMARD treatment. The upper, middle, and lower lines of the box corresponds to the third quartile, median, and first quartile of the diversity index of patients in each stratified group, respectively.

(a)

(b)